{"created":"2023-05-15T16:40:04.346652+00:00","id":14189,"links":{},"metadata":{"_buckets":{"deposit":"09bad8f2-8b08-4005-b8af-36f28c31be3a"},"_deposit":{"created_by":2,"id":"14189","owners":[2],"pid":{"revision_id":0,"type":"depid","value":"14189"},"status":"published"},"_oai":{"id":"oai:nagasaki-u.repo.nii.ac.jp:00014189","sets":["29:30"]},"author_link":["51201","51202","51197","51196","51195","51198","51194","51200","51193","51199"],"item_2_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2010-09","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"9","bibliographicPageEnd":"1409","bibliographicPageStart":"1404","bibliographicVolumeNumber":"5","bibliographic_titles":[{"bibliographic_title":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer"}]}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"INTRODUCTION: We assessed the relationship between the plasma concentration of gefitinib and its efficacy in Japanese patients with advanced non-small cell lung cancer (NSCLC). METHODS: Plasma trough levels of gefitinib were measured on days 3 (D3) and 8 (D8) by high-performance liquid chromatography in 44 patients with advanced NSCLC treated with 250 mg gefitinib daily. Eligibility criteria included performance status < or =3, age < or = 80 years, and stages IIIB-IV cancer. Epidermal growth factor receptor mutations in 23 patients were analyzed retrospectively. RESULTS: The median plasma gefitinib values were 662 ng/ml on D3 and 1064 ng/ml on D8, and the D8/D3 ratio was 1.587. The median progression-free survival (PFS) was 71 days, and the median overall survival was 224 days. Adenocarcinoma, never smoking, and high D8/D3 ratio were associated with better PFS. Multivariate analysis showed that PFS was associated with never smoking and high D8/D3 ratio. Never-smokers with a high D8/D3 ratio showed the best PFS. Overall survival was not associated with the D8/D3 ratio. Epidermal growth factor receptor mutation analysis of 23 patients showed that 15 patients had exon 19 deletion and/or exon 21 point mutation. Median PFS was similar between mutation-positive and mutation-negative individuals in the high D8/D3 group, whereas mutation-negative individuals in the low D8/D3 group showed the worst median PFS. CONCLUSIONS: A high D8/D3 ratio was independently associated with better PFS in patients with NSCLC treated with gefitinib. Our findings suggest that the pharmacokinetics of gefitinib may be involved in its antitumor activity.","subitem_description_type":"Abstract"}]},"item_2_description_63":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"Journal of thoracic oncology, 5(9), pp.1404-1409; 2010","subitem_description_type":"Other"}]},"item_2_publisher_33":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"the International Association for the Study of Lung Cancer"}]},"item_2_relation_11":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"20651613","subitem_relation_type_select":"PMID"}}]},"item_2_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1097/JTO.0b013e3181e59a7b","subitem_relation_type_select":"DOI"}}]},"item_2_rights_13":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"© 2010 by the International Association for the Study of Lung Cancer."},{"subitem_rights":"This is a non-final version of an article published in final form in Journal of thoracic oncology, 5(9), pp.1404-1409; 2010."}]},"item_2_source_id_10":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AA12058455","subitem_source_identifier_type":"NCID"}]},"item_2_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"15560864","subitem_source_identifier_type":"ISSN"}]},"item_2_version_type_16":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Nakamura, Yoichi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Sano, Kazumi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Soda, Hiroshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Takatani, Hiroshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Fukuda, Minoru"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Nagashima, Seiji"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Hayashi, Tomayoshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Oka, Mikio"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Tsukamoto, Kazuhiro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kohno, Shigeru"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-12-22"}],"displaytype":"detail","filename":"JTO5_1404.pdf","filesize":[{"value":"267.2 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"JTO5_1404.pdf","url":"https://nagasaki-u.repo.nii.ac.jp/record/14189/files/JTO5_1404.pdf"},"version_id":"31fde9ed-4283-49c7-ade8-7a4578fe3dc0"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Chemotherapy","subitem_subject_scheme":"Other"},{"subitem_subject":"EGFR mutation","subitem_subject_scheme":"Other"},{"subitem_subject":"Gefitinib","subitem_subject_scheme":"Other"},{"subitem_subject":"Non-small cell lung cancer","subitem_subject_scheme":"Other"},{"subitem_subject":"Pharmacokinetics","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer.","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer."}]},"item_type_id":"2","owner":"2","path":["30"],"pubdate":{"attribute_name":"公開日","attribute_value":"2011-10-03"},"publish_date":"2011-10-03","publish_status":"0","recid":"14189","relation_version_is_last":true,"title":["Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer."],"weko_creator_id":"2","weko_shared_id":-1},"updated":"2023-05-16T00:24:03.814050+00:00"}